RESUMO
Multiple Myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We established a harmonized consortium to generate an Immune Atlas of MM aimed at informing disease etiology, risk stratification, and potential therapeutic strategies. We generated a transcriptome profile of 1,149,344 single cells from the bone marrow of 263 newly diagnosed patients enrolled in the CoMMpass study and characterized immune and hematopoietic cell populations. Associating cell abundances and gene expression with disease progression revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing patients. Furthermore, signaling analyses suggested active intercellular communication involving APRIL-BCMA, potentially promoting tumor growth and survival. Finally, we demonstrate that integrating immune cell levels with genetic information can significantly improve patient stratification.
RESUMO
Proper axonal branch growth and targeting are essential for establishing a hard-wired neural circuit. Here, we examined the role of Fibroblast Growth Factor Receptors (FGFRs) in axonal arbor development using loss of function and overexpression genetic analyses within single neurons. We used the invariant synaptic connectivity patterns of Drosophila mechanosensory neurons with their innate cleaning reflex responses as readouts for errors in synaptic targeting and circuit function. FGFR loss of function resulted in a decrease in axonal branch number and lengths, and overexpression of FGFRs resulted in ectopic branches and increased lengths. FGFR mutants produced stereotyped axonal targeting errors. Both loss of function and overexpression of FGFRs within the mechanosensory neuron decreased the animal's frequency of response to mechanosensory stimulation. Our results indicate that FGFRs promote axonal branch growth and proper branch targeting. Disrupting FGFRs results in miswiring and impaired neural circuit function.
Assuntos
Axônios/metabolismo , Drosophila melanogaster/metabolismo , Receptores de Fatores de Crescimento de Fibroblastos/metabolismo , Animais , Proteínas de Drosophila/metabolismo , Ligantes , Mecanorreceptores/metabolismo , Mutação/genética , Rede Nervosa/metabolismo , Reflexo , Sinapses/metabolismoRESUMO
It has been hypothesized that oxidative imbalance and alterations in nitrergic signaling play a role in the neurobiology of schizophrenia. Preliminary evidence suggests that adjunctive minocycline treatment is efficacious for cognitive and negative symptoms of schizophrenia. This study investigated the effects of minocycline in the prevention and reversal of ketamine-induced schizophrenia-like behaviors in mice. In the reversal protocol, animals received ketamine (20 mg/kg per day intraperitoneally or saline for 14 days, and minocycline (25 or 50 mg/kg daily), risperidone or vehicle treatment from days 8 to 14. In the prevention protocol, mice were pretreated with minocycline, risperidone or vehicle prior to ketamine. Behaviors related to positive (locomotor activity and prepulse inhibition of startle), negative (social interaction) and cognitive (Y maze) symptoms of schizophrenia were also assessed. Glutathione (GSH), thiobarbituric acid-reactive substances (TBARS) and nitrite levels were measured in the prefrontal cortex, hippocampus and striatum. Minocycline and risperidone prevented and reversed ketamine-induced alterations in behavioral paradigms, oxidative markers (i.e. ketamine-induced decrease and increase in GSH levels and TBARS content, respectively) as well as nitrite levels in the striatum. These data provide a rationale for evaluating minocycline as a novel psychotropic agent and suggest that its mechanism of action includes antioxidant and nitrergic systems.
Assuntos
Antioxidantes/metabolismo , Ketamina , Minociclina/farmacologia , Óxido Nítrico/metabolismo , Esquizofrenia/tratamento farmacológico , Esquizofrenia/prevenção & controle , Psicologia do Esquizofrênico , Animais , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Antipsicóticos/farmacologia , Antipsicóticos/uso terapêutico , Corpo Estriado/metabolismo , Quimioterapia Combinada , Glutationa/metabolismo , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Masculino , Aprendizagem em Labirinto , Camundongos , Minociclina/uso terapêutico , Atividade Motora/efeitos dos fármacos , Nitritos/análise , Córtex Pré-Frontal/efeitos dos fármacos , Córtex Pré-Frontal/metabolismo , Risperidona/farmacologia , Risperidona/uso terapêutico , Esquizofrenia/metabolismo , Filtro Sensorial/efeitos dos fármacos , Comportamento Social , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismoRESUMO
Vascular Dementia (VaD) and Vascular Cognitive Impairment (VCI) are increasingly common worldwide. Nevertheless, the clinical-neuropsychiatric profile of these patients at presentation is still poorly characterized in developing countries. OBJECTIVE: We aimed to characterize the prevalence of neuropsychiatric symptoms, as well as the clinical and cognitive profile of patients with VaD and VCI in our tertiary University outpatient cognitive clinic. METHODS: We reviewed data on 253 patients diagnosed with VaD or VCI at our center between January 1996 and December 2005, located in an industrial region of the state of Sao Paulo, southeast Brazil. We excluded 19 patients who did not complete the medical investigation or who did not meet the clinical or neuroimaging criteria for vascular dementia. We collected socio-demographic data, educational level, vascular risk factors, behavioral and neuropsychological symptoms and cognitive complaints at presentation. RESULTS: Two hundred and thirty-four cases were included in this analysis. The mean age was 67.77±10.35 years; 72% were males and 82% had less than four years of education (average 2.84±2.96 years). The initial Clinical Dementia Rating score was 2 & 3 in 68%. A total of 185 patients had neuropsychiatric symptoms distributed in main categories as follows: psychosis (52.6%), hallucinations (23.5%), psychomotor agitation (22.5%), depression (17.5%) and apathy (17.5%). Hypertension and previous stroke were the most prevalent risk factors. CONCLUSION: We found a high prevalence of neuropsychiatric symptoms. The clinical-neuropsychiatric profile of patients presenting to cognitive clinics in developing countries may differ greatly to that of more developed nations. These characteristics may have implications for public health strategies.
Demência Vascular (DV) e comprometimento cognitivo vascular (CCV) são diagnósticos cada vez mais relatados em todos os continentes. Entretanto, o perfil dos sintomas comportamentais e psicológicos das demências (SCPD) nos pacientes com DV é ainda pouco descrito e caracterizado, nos países em desenvolvimento. OBJETIVO: Determinar a prevalência dos SCPD, o perfil de manifestações neuropsiquiátricas e cognitivas, nos pacientes com DV no ambulatório de Neurologia Cognitiva e Comportamental (ANCC), do Hospital das Clínicas da Universidade de São Paulo em Ribeirão Preto (HCRP-FMUSP). MÉTODOS: Revisamos os prontuários de 253 pacientes diagnosticados com DV ou CCV atendidos entre janeiro de 1996 e dezembro de 2005. Excluímos 19 pacientes que não completaram a investigação diagnóstica, não preencheram os critérios clínicos do DSM-IV, e neuroimagem não disponível para análise. Coletamos dados sócio-demográficos, nível de escolaridade, fatores de risco vascular, e SCPD da consulta de admissão. RESULTADOS: 234 pacientes foram incluídos nesta análise. A idade média global foi de 67,77±10,35; com 38% de mulheres; escolaridade de 2,84±2,96 anos; MEEM inicial 13,22±7,00, e 68% de CDR 2 & 3. 79% de pacientes com SCPD foram divididos nas seguintes categorias: psicose (52,6%), alucinações (23,5%), agitação (22,2%), depressão (17,5%) e apatia (17,5%) foram às manifestações mais prevalentes. Hipertensão Arterial e AVC prévio foram os fatores de risco de maior prevalência. CONCLUSÃO: Verificou-se elevada prevalência de SCPD em DV. O perfil destas alterações neuropsiquiátricas na DV mostrou uma tendência na direção de sintomatologia psicótica, devendo ser objeto de mais pesquisas, pois os padrões em nações desenvolvidas podem ser substancialmente diferentes.
RESUMO
Pemphigus vulgaris is a systemic auto-immune medical condition that mainly manifests with changes in skin and vasculopathy. This is a case report of a 69-year-old male with confirmed histopathologic diagnosis of Pemphigus vulgaris presenting ulterior Cognitive Impairment, mostly in executive function. The patient was treated using steroids, immunomodulatory therapy, fluoxetine and galantamine. Neuropsychological testing and magnetic resonance (MRI) were performed. This is the first report of correlational cognitive impairment with Pemphigus vulgaris in the literature. Physicians should be aware of vascular causes for cognitive impairment in patients presenting auto-immune conditions.
Phemphigus vulgaris é uma condição médica sistêmica autoimune que principalmente se manifesta com alterações de pele e vasculopatia. Este é um caso de um homem de 69 anos com diagnóstico histopatológico de Phemphigus vulgaris apresentando posterior comprometimento cognitivo, predominante em funções executivas. O paciente foi tratado com esteroides, terapia imunomoduladora, fluoxetina e galantamina. Avaliação neuropsicológica e ressonância magnética foram realizados. Este é o primeiro relato correlacionando comprometimento cognitivo a pênfigo vulgar na literatura. Os clínicos devem estar cientes das causas vasculares para comprometimento cognitivo em pacientes se apresentando com condições autoimunes.